Advancing
a New Front
in the War against Cancer

Provectus Biopharmaceuticals is
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects


PV-10

An Investigational Drug for Cancer

PH-10

An Investigational Drug for Psoriasis and Atopic Dermatitis

IN THE MEDIA

June 16, 2015

BIO International Convention 2015 Presentation Slides Available

Provectus presented at the BIO International Convention 2015 in Philadelphia on June 16, 2015 at 10:45 AM EDT.

June 15, 2015

Provectus Begins Patient Enrolment for Phase 3 Trial of PV-10 for Melanoma

A Melanoma News Today article reports on the comencement of enrollment for a phase 3 trial of PV-10 for locally advanced cutaneous melanoma.

June 4, 2015

Novel Data On PV-10 For Melanoma Treatment Presented At ASCO

A Melanoma News Today article reports on a presentation entitled "A Changing Topography: The Role of Intralesional Therapy in Melanoma" that was presented by Dr. Sanjiv Agarwala at ASCO 2015. In the presentation, Dr. Agarwala showed phase 2 findings for PV-10, showing the drug accumulated within cancer cells but not normal cells, inducing acute autophagy and exposing antigenic tumor fragments to antigenic presenting cells (APCs).

May 28, 2015

Rose Bengal for melanoma treatment: will it translate to the clinic?

In an article appearing in Melanoma Management, Dr. Sanjib Agarwala discusses the potential clinical benefits of PV-10 for melanoma, stating "The promise suggested by the research to date is compelling - and if confirmed, translating these benefits to the clinic is a high priority."

May 20, 2015

Asia Biotech Invest Conference Presentation Slides Available

Provectus presented at the Asia Biotech Invest Conference in Hong Kong on May 20, 2015 at 10:00 AM HKT.

May 19, 2015

Provectus taking novel path to treat cancer

A recent BioTuesday article discusses Provectus' novel approach of using physical chemistry and a different basis for the mechanism of action of its Rose Bengal based investigational anti-cancer agents, including PV-10, currently in phase 3 clinical testing.

May 19, 2015

Intralesional therapy for metastatic melanoma - ModernMedicine

Kate's Foundation created a news brief on last week's Modern Medicine/Dermatology Times article on treating metastatic melanoma with investigational drug PV-10.

May 15, 2015

Intralesional therapy for metastatic melanoma

An article appearing in Dermatology Times titled "Intralesional therapy for metastatic melanoma" discusses the "bystander" effect seen in clinical testing of intralesional PV-10 for melanoma and clinical evidence from studies at Moffitt Cancer Center that intralesional PV-10 induces a systemic immune response.

May 14, 2015

Audio: Dr. Sanjiv Agarwala Interviewed on iHeart Radio 24/7 News

In support of Melanoma Awareness Month, an interview of Dr. Sanjiv Agarwala was aired on iHeart Radio 24/7 News on May 7, 2015.

May 14, 2015

Audio: PV-10 Phase 3 Enrollment Info Aired on WAEB in Allentown, PA

Beginning May 4, 2015, an ad was aired on WAEB NewsRadio 790 in Allentown, PA informing the community that Provectus is seeking patients for the phase 3 trial of PV-10 for melanoma and that patients may now enrol at St. Luke's University Hospital and Health Network in Bethlehem, PA.

May 14, 2015

Audio: Dr. Sanjiv Agarwala Discusses Melanoma on Talk with Audrey

Audrey Adams recently interviewed Sanjiv Agarwala, MD on the syndicated radio program Talk With Audrey.

May 14, 2015

Commentary: Intralesional Melanoma Treatments Are Ready for Prime Time

A DDN News article discusses the intralesional drug candidates, including PV-10, that are currently being investigated for advanced melanoma treatment.

May 7, 2015

Webcast: Q1 2015 Quarterly Business Update Conference Call

Provectus will hold its quarterly business update conference call at 4 p.m. (EDT) May 7, 2015 to provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors.

May 7, 2015

May is National Melanoma Skin Cancer Prevention Month

In recognition of National Melanoma Skin Cancer Prevention Month, Melanoma News Today reports on promising new strategies for the treatment of melanoma, including PV-10.

May 4, 2015

BioCentury Updates Clinical Status for Provectus

The Clinical News section of the April 27, 2015 edition of BioCentury included a clinical status update for Provectus reporting the initiation of a phase 3 trial of PV-10 for melanoma.

May 4, 2015

Novel Therapies Are Giving New Hope for Patients with Advanced Melanoma

A Newswise article announces that Dr. Sanjiv Agarwala is available for media interview to discuss cutting-edge treatments that represent the recent surge in research aimed at battling late stage melanoma.

April 22, 2015

Provectus prioritizes pharma partners with clinical-stage PD1/PDL1s

A BioPharm Insight article reports on Provectus efforts to partner with companies having PD1 or PDL1 inhibitor agents in late-stage development, noting the recently approved joint patent with Pfizer covering the use of PV-10 in combination with systemic inhibitors of immune system regulation.

April 22, 2015

Provectus Biopharmaceuticals, Pfizer Receive Patent Allowance for Use of PV-10 in Combination with Systemic Immunotherapy Agents in Treatment of Cancer

Dermwire covers news that Provectus an Pfizer have received allowance from the FDA for a jointly held patent protecting the use of PV-10 in combination with systemic inhibitors of immune system regulation.

April 17, 2015

Audio Recording of Provectus Panel Discussion Now Available

An audio recording of Provectus' panel discussion on Thursday, April 9, 2015 at The Harvard Club of New York City is now available.

April 16, 2015

Provectus Opens Phase 3 Trial Enrollment for Investigational Melanoma Agent

Dermwire covers news that Provectus has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma.

more...

PRESS RELEASES

July 2, 2015

Provectus Biopharmaceuticals Signs Letter of Intent with Boehringer Ingelheim (China) to Collaborate in Bringing PV-10 to Market in China

Provectus announced today that it has signed a Letter of Intent (the "LOI") with Boehringer Ingelheim (China) Investment Co. Ltd. ("Boehringer").

July 2, 2015

Provectus Biopharmaceuticals' Data on PV-10 for Chemoablation of Liver Cancers Presented at ESMO 17th World Congress on Gastrointestinal Cancer

Provectus announced that data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma (HCC) and cancer metastatic to the liver was presented at the ESMO 17th World Congress on Gastrointestinal Cancer (ESMO-GI).

June 26, 2015

AAPI Honors Provectus Biopharmaceuticals During 33rd Annual Convention and Scientific Assembly

The American Association of Physicians of Indian Origin ("AAPI") honored Provectus Biopharmaceuticals, Inc. at a gala during the AAPI's 33rd Annual Convention and Scientific Assembly on Friday, June 19, 2015.

June 26, 2015

Provectus Biopharmaceuticals' Data on PV-10 as Treatment for Melanoma Presented at 5th European Post-Chicago Melanoma / Skin Cancer Meeting

Provectus today announced that Dr. Vernon Sondak (Moffitt Cancer Center, Tampa, FL, USA) presented data on "Intralesional Therapy for Melanoma with PV-10" during the 5th European Post-Chicago Melanoma/Skin Cancer Meeting in Munich, Germany.

June 25, 2015

Provectus Biopharmaceuticals' Poster Presentation Displayed on Phase 3 Study of PV-10 at 5th European Post-Chicago Melanoma / Skin Cancer Meeting

Provectus announced that its poster presentation titled "Trials in Progress: Intralesional Rose Bengal vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma" is on display at the 5th European Post-Chicago Melanoma / Skin Cancer Meeting in Munich, Germany.

June 24, 2015

Provectus Biopharmaceuticals Announces Abstract Available on PV-10 for Chemoablation of Liver Cancers at ESMO 17th World Congress on Gastrointestinal Cancer

Provectus announced that the abstract titled, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver" to be presented at the ESMO 17th World Congress on Gastrointestinal Cancer is now available online at: http://annonc.oxfordjournals.org/content/26/suppl_4/iv33.1.full?sid=82267ebd-da5c-4a1a-9320-a795571b6085

June 24, 2015

Provectus Biopharmaceuticals, Inc. Announces Closing of Public Offering

Provectus announced today that it has completed its public offering of 17,500,000 shares of common stock and warrants to purchase 17,500,000 shares of common stock at a price to the public of $0.75 for a fixed combination of one share of common stock and a warrant to purchase one share of common stock.

June 22, 2015

Provectus Biopharmaceuticals Retains PharmaHEALTHLabs to Facilitate Investigator Advisory Board Meeting During 11Th Brazilian Melanoma Conference

Provectus announced that it has retained healthcare communications company PharmaHEALTHLabs to coordinate and facilitate an Investigator Advisory Board meeting to be held during 11th Brazilian Melanoma Conference from August 13-15, 2015 in Goiania, Brazil.

June 19, 2015

Provectus Biopharmaceuticals, Inc. Announces Pricing of Public Offering to Raise $13.1 Million

Provectus today announced the pricing of an underwritten public offering of 17,500,000 shares of common stock and warrants to purchase 17,500,000 shares of common stock with a public offering price of $0.75 for a fixed combination of one share of common stock and a warrant to purchase one share of common stock.

June 18, 2015

Provectus Biopharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants

Provectus today announced that it intends to offer and sell shares of its common stock and warrants to purchase common stock, subject to market and other conditions, in an underwritten public offering. Provectus intends to use the net proceeds of the offering for clinical development, working capital and general corporate purposes.

June 16, 2015

Abstract on Provectus Biopharmaceuticals' PV-10 in Colon Cancer Models Published by Society of Surgical Oncology

Provectus announced that the Society of Surgical Oncology (SSO) has published an abstract describing preliminary research into use of the Company's investigational agent, PV-10, in murine models of colon cancer.

June 11, 2015

Provectus Biopharmaceuticals to Present at 2015 BIO International Convention in Philadelphia

Provectus announced today that it will present at the 2015 BIO International Convention on Tuesday, June 16, at 10:45 am Eastern.

June 2, 2015

Provectus Biopharmaceuticals Retains Allison+Partners as New Media Relations Consultant

Provectus announced today that it has retained Allison+Partners as its new media relations consultant.

June 1, 2015

Provectus Biopharmaceuticals' Data on PV-10 as Intralesional Treatment of Melanoma Presented at 2015 American Society of Clinical Oncology Annual Meeting

Provectus announced today that Dr. Sanjiv Agarwala, chief of medical oncology and hematology at St. Luke's Cancer Center in Bethlehem, Pennsylvania, and professor of medicine at Temple University School of Medicine in Philadelphia, presented data on PV-10 as an investigational intralesional treatment of melanoma at the 2015 American Society of Clinical Oncology's Annual Meeting on May 31, 2015.

May 28, 2015

Provectus Biopharmaceuticals' Abstract on Liver Cancer Accepted for Poster Presentation at 6th Asia-Pacific Primary Liver Cancer Expert Meeting

Provectus announced today that the organizing committee of the 6th Asia-Pacific Primary Liver Cancer Expert Meeting has accepted the Company's abstract "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver", for a poster presentation.

May 27, 2015

Provectus Biopharmaceutical's Abstract Accepted for Poster Presentation at 5th European Post-Chicago Melanoma / Skin Cancer Meeting

Provectus today announced that the presentation committee of the 5th European Post-Chicago Melanoma / Skin Cancer Meeting has accepted its abstract titled "Trials in Progress: Intralesional Rose Bengal vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma."

May 18, 2015

Provectus Biopharmaceuticals Extends for Additional 60 Days Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-Think Pharmaceutical Co., Ltd

Provectus today announced that it had extended for an additional 60 days its Memorandum of Understanding with with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group.

May 14, 2015

Provectus Biopharmaceuticals' Poster Presentation on PV-10 Clinical Data from Phase 1 Study for Cancers of the Liver Scheduled for Thursday, July 2, 2015 at 17th World Congress on Gastrointestinal Cancer

Provectus announced today that the abstract titled, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver," to be presented at the European Society for Medical Oncology's 17th World Congress on Gastrointestinal Cancer, is scheduled for Thursday, July 2, 2015 from 10:30 to 11:00 a.m. and 4:55 to 5:25 p.m. local time. Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Health Network, Bethlehem, PA, will be the presenter.

May 8, 2015

Provectus Biopharmaceuticals Updates Market on Business Developments

Provectus provided the market with a business update in its quarterly investor conference call held on Thursday, May 7, 2015, that addresses several matters in conjunction with the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.

May 7, 2015

Provectus Biopharmaceuticals Reports First Quarter Financial Results

Provectus today announced its results of operations and financial condition for the first quarter ended March 31, 2015.

more...